Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Henry Schein's stronger Q2 sales and margins prompt a 2026 outlook hike, but second-half savings execution remains key to sustaining earnings momentum.

Align's $37.5M U.K. VAT liability, new 20% VAT charges and pending appeal add fresh earnings uncertainty amid currency and mix pressures.

Dentsply Sirona’s second quarter results were met with a negative market reaction, as shares declined following revenue and non-GAAP earnings that exceeded Wall Street expectations. Management attributed the year-on-year revenue decline primarily to lower sales volumes in key product segments and regions, especially in the Americas and EMEA, and highlighted ongoing challenges in capital equipment demand and inventory reduction by distributor partners. CEO Daniel Scavilla described the company’s

Revenue declined 4.1% as restructuring efforts begin to take hold.

Dental products company Dentsply Sirona (NASDAQ:XRAY) announced better-than-expected revenue in Q2 CY2026, but sales fell by 4.1% year on year to $898 million. On the other hand, the company’s full-year revenue guidance of $3.55 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $0.52 per share was 50.1% above analysts’ consensus estimates.

Shares of dental products company Dentsply Sirona (NASDAQ:XRAY) fell 6.8% in the afternoon session after the company reported second-quarter 2026 earnings, which featured a beat on profit estimates, was overshadowed by a weak full-year revenue forecast.

DENTSPLY SIRONA (NASDAQ:XRAY) reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europ

Earnings trigger and recent business updates DENTSPLY SIRONA (XRAY) is in focus after reporting second quarter 2026 earnings on 6 August, alongside reaffirmed full year net sales guidance and an update on long running share repurchases. The company reported quarterly sales of US$898 million compared with US$936 million a year earlier. Net income for the quarter was US$37 million compared with a net loss of US$45 million in the prior year period, with basic and diluted earnings per share from...

DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.

The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Moby summary of DENTSPLY SIRONA Inc.'s Q2 2026 earnings call

Dentsply (XRAY) delivered earnings and revenue surprises of +44.44% and +1.60%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Dental products company Dentsply Sirona (NASDAQ:XRAY) reported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 4.1% year on year to $898 million. On the other hand, the company’s full-year revenue guidance of $3.55 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $0.52 per share was 50.1% above analysts’ consensus estimates.

XRAY's Q2 results are likely to reflect transformation investments, dealer inventory cuts and weak implants, while Wellspect growth offers support.

Ariel Investments, an investment management company, released its “Ariel Focus Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund returned 2.14% in the second quarter of 2026, underperforming the Russell 1000 Value and S&P 500, which gained 13.87% and 15.20%, respectively. The fund benefited from gains in several […]

Dentsply Sirona has been treading water for the past six months, recording a small loss of 0.5% while holding steady at $12.66. The stock also fell short of the S&P 500’s 7.9% gain during that period.